214
Participants
Start Date
February 22, 2018
Primary Completion Date
June 30, 2023
Study Completion Date
June 30, 2023
ALXN1840
ALXN1840 administered orally in 15 mg tablets
SoC Therapy
Depending on the site/region, participants randomized to receive SoC treatment will receive trientine, penicillamine, Zinc, or a combination of these medicines, administered according to standard regimens.
Research Site, Taoyuan
Research Site, Hong Kong
Research Site, Grafton
Research Site, Budapest
Research Site, Vienna
Research Site, Concord
Research Site, Parkville
Research Site, Adelaide
Research Site, Innsbruck
Research Site, Graz
Research Site, Århus N
Research Site, Taipei
Research Site, Belgrade
Research Site, Hamburg
Research Site, Málaga
Research Site, Istanbul
Research Site, Istanbul
Research Site, Izmir
Research Site, Daegu
Research Site, Ann Arbor
Research Site, Chicago
Research Site, Bron
Research Site, Paris
Research Site, Houston
Research Site, Los Angeles
Research Site, Seattle
Research Site, Moscow
Research Site, Moscow
Research Site, Moscow
Research Site, Singapore
Research Site, Saint Petersburg
Research Site, Nizhny Novgorod
Research Site, Ramat Gan
Research Site, Jerusalem
Research Site, New Haven
Research Site, Parkville
Research Site, Toronto
Research Site, Prague
Research Site, Heidelberg
Research Site, Leipzig
Research Site, Chiba
Research Site, Kumamoto
Research Site, Kurume-shi
Research Site, Matsuyama
Research Site, Meguro-ku
Research Site, Sapporo
Research Site, Takatsuki-shi
Research Site, Yokohama
Research Site, Warsaw
Research Site, Warsaw
Research Site, Barcelona
Research Site, Sabadell
Research Site, Ankara
Research Site, Edgbaston
Research Site, Guildford
Research Site, London
Lead Sponsor
Alexion Pharmaceuticals, Inc.
INDUSTRY